Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2014 by Yasushi Yamamoto, Corundum is based in the United States and operates as an international innovation group. The firm focuses on convergence across science, technology, and business, with a commitment to supporting life-changing discoveries. Corundum manages multiple innovation hubs and engages in various investment and research activities.
Corundum invests in pre-seed to Series A stages, primarily in healthcare, biotech, and AI sectors. Their key areas of interest include neuroscience and systems biology, with a focus on personalized medicine and mental health challenges. The firm operates through four innovation hubs, providing venture investment, consulting, and venture philanthropy.
Corundum's portfolio includes early investment vehicles like Corundum Neuroscience (CNS), which targets breakthroughs in neuroscience, and Corundum Systems Biology (CSB), which explores the human microbiome's impact on brain health. These hubs collaborate with leading innovators to drive scientific discovery.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.